SR-9009 (Stenabolic)

Research Profile

SR-9009 was developed at the Scripps Research Institute by Professor Thomas Burris. As a Rev-ErbAα/β agonist, it modulates the expression of genes governing circadian rhythm, lipid and glucose homeostasis, and inflammatory responses. In animal models, SR-9009 has demonstrated reductions in fat mass, improvements in endurance capacity, and favorable effects on cholesterol and triglyceride levels — all without changes in food intake. By enhancing mitochondrial activity in muscle tissue, it effectively increases the metabolic rate. Its mechanism is entirely distinct from androgen-receptor-based compounds, making it a complementary research tool for metabolic studies.